Selective internal radiation therapy using yttrium-90 microspheres for the treatment of primary or metastatic liver malignancies
Nachtnebel A, Sotti G, Vitale A, Perrini MR
Record ID 32011001045
English, German
Authors' recommendations:
Based on the evidence identified, the inclusion of TheraSphere® for the treatment of HCC in the catalogue of benefits was not currently recommended. The evidence for the treatment of mCRC with SIR-Spheres® indicated that is more efficacious and as safe as other treatment options. An inclusion in the catalogue of benefits was therefore recommended with restrictions.
Details
Project Status:
Completed
URL for project:
http://eprints.hta.lbg.ac.at/922
Year Published:
2011
URL for published report:
http://eprints.hta.lbg.ac.at/921
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Humans
- Liver Neoplasms
- Radiotherapy
- Yttrium Radioisotopes
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.